文摘
Activation of peroxisome proliferator-activated receptor x3b3; (PPARx3b3;) by ligands is associated with beneficial health effects, including anti-inflammatory and insulin-sensitizing effects. The aim of the current study was to develop luciferase reporter gene assays to enable fast and low-cost measurement of PPARx3b3; agonist and antagonist activity. Two reporter gene assays, PPARx3b3;1 CALUX and PPARx3b3;2 CALUX, were developed by stable transfection of U2OS cells with an expression vector for PPARx3b3;1 or PPARx3b3;2 and a pGL3–3xPPRE–tata-luc or pGL4–3xPPRE–tata-luc reporter construct, respectively. PPARx3b3;1 CALUX and PPARx3b3;2 CALUX cells showed similar concentration-dependent luciferase induction upon exposure to the PPARx3b3; agonists rosiglitazone, troglitazone, pioglitazone, ciglitazone, netoglitazone, and 15-deoxy-Δ12,14-prostaglandin J2. The potency to induce luciferase decreased in the following order: rosiglitazone > troglitazone = pioglitazone > netoglitazone > ciglitazone. A concentration-dependent decrease in the response to 50 nM rosiglitazone was observed on the addition of PPARx3b3; antagonist GW9662 or T0070907 in both PPARx3b3;1 CALUX and PPARx3b3;2 CALUX cells. The PPARα agonists WY14643 and fenofibrate failed to induce luciferase activity, confirming the specificity of these cell lines for PPARx3b3; agonists. In conclusion, PPARx3b3;1 CALUX and PPARx3b3;2 CALUX cells provide a reliable and useful tool to screen (bio)chemicals for PPARx3b3; agonist or antagonist activity.